Welcome to our dedicated page for Sanofi FR SEC filings (Ticker: SNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanofi (SNY) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ and EURONEXT. Sanofi files annual reports on Form 20-F and frequent Form 6-K current reports that incorporate press releases, financial statements, and transaction documents by reference. These filings help investors track Sanofi’s operations as an R&D driven, AI-powered biopharma company focused on medicines and vaccines in immunology, autoimmune disease, rare disease, diabetes, respiratory conditions, and other areas.
Recent 6-K filings referenced in the available data include current reports attaching press releases on product approvals and recommendations (such as Wayrilz for immune thrombocytopenia, Qfitlia and Cablivi approvals in China, and high-dose influenza vaccine data), clinical and regulatory updates for pipeline assets (including tolebrutinib and efdoralprin alfa), and corporate transactions such as the completed acquisition of Vicebio and the planned acquisition of Blueprint Medicines. Other 6-Ks describe debt offerings, including the issuance and pricing of multiple series of fixed and floating rate notes under an indenture, along with the related underwriting agreement and legal opinions.
Sanofi’s interim financial information is also furnished on Form 6-K, including unaudited condensed half-year consolidated financial statements prepared under IFRS. These documents discuss topics such as discontinued operations, joint ventures, contingent consideration, royalties, and financial instruments. Together, the filings provide a detailed view of Sanofi’s capital structure, financing activities, product pipeline progress, and geographic footprint.
On this page, Stock Titan surfaces Sanofi’s latest SEC filings as they are made available from EDGAR and applies AI-powered summaries to help explain the contents of lengthy documents. Users can quickly identify key points in 20-F annual reports, 6-K current reports, and related exhibits, and can review how clinical, regulatory, and financing events are reflected in Sanofi’s official disclosures.
Amundi and Amundi Asset Management filed an amended Schedule 13G reporting beneficial ownership of 62,741,607 Sanofi common shares and ADRs, representing 5.11% of the class. They report no sole voting or dispositive power, with 31,006,825 shares subject to shared voting power and 62,741,607 shares subject to shared dispositive power.
The filing explains that 27,972,813 of these shares are held through a French employee investment vehicle (FCPE) dedicated to Sanofi employees, where voting rights are exercised by the FCPE supervisory board rather than Amundi. Amundi certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Sanofi.
Sanofi has filed its annual report on Form 20-F, outlining 2025 results and a wide range of risks that could affect future performance. The company prepares its consolidated accounts under IFRS and emphasizes that forward-looking statements are highly uncertain.
Sanofi spent €7,842 million on research and development in 2025, equal to 18.0% of net sales, while its key drug Dupixent generated net sales of €15,714 million, or 36.0% of total net sales. The United States represented 50.8% of net sales, underscoring exposure to US pricing and policy changes.
The report details major risks: product liability litigation, tightening global regulation, intellectual property challenges, cyber and data-privacy threats, complex manufacturing and supply chains, climate and geopolitical disruptions, and heavy dependence on a few blockbuster products. Sanofi highlights growing pressure from US and European pricing policies, including an MFN agreement with the US government and the Inflation Reduction Act, as significant long-term headwinds.
Sanofi reported that its BTK inhibitor Wayrilz (rilzabrutinib) received FDA breakthrough therapy designation in the US and orphan drug designation in Japan for treating warm autoimmune hemolytic anemia (wAIHA), a rare autoimmune disease that destroys red blood cells and can cause serious complications.
Both designations are based on clinical data from the ongoing LUMINA 2 phase 2b study, with a new LUMINA 3 phase 3 trial comparing rilzabrutinib to placebo in wAIHA. Rilzabrutinib is already approved as Wayrilz for immune thrombocytopenia (ITP) in the US, EU, and UAE, and remains investigational for wAIHA and other rare immune-mediated diseases.
Sanofi announced a major leadership transition, with its Board deciding not to renew Paul Hudson’s Director mandate, making February 17, 2026 his last day as Chief Executive Officer. The Board has appointed Belén Garijo as the new CEO, with her term starting after the Annual General Meeting on April 29, 2026, subject to shareholder approval of her appointment as a director and an amendment to the articles of association regarding the CEO age limit. During the transition, Olivier Charmeil, Executive Vice President, General Medicines, will serve as Interim CEO. Sanofi highlights Garijo’s global pharmaceutical leadership experience and states that her priorities will include strengthening productivity, governance, and the innovation capacity of Research & Development.
Sanofi filed a Form 13F reporting its role as an institutional investment manager. The report lists 8 holdings with an aggregate market value of $310,414,825. The filing is signed by Alexandra Roger, Head of Legal Corporate & Finance, in Paris on 02-11-2026.
Sanofi has completed its acquisition of Dynavax Technologies Corporation, adding the marketed adult hepatitis B vaccine HEPLISAV‑B and a shingles vaccine candidate (Z‑1018), along with additional vaccine pipeline projects. The transaction is intended to strengthen Sanofi’s position in adult immunization by combining Dynavax’s products with Sanofi’s global commercial and development capabilities.
The tender offer for all outstanding Dynavax common shares expired on February 9, 2026, and Sanofi accepted and will pay $15.50 per share in cash, without interest and subject to applicable taxes, for all validly tendered shares and, via a follow‑on merger, for all remaining shares. Dynavax has become an indirect, wholly owned Sanofi subsidiary, and its common stock will cease trading on the NASDAQ Global Select Market as of February 10, 2026.
Sanofi, through Samba Merger Sub, has successfully completed its cash tender offer for Dynavax Technologies at $15.50 per share. The purchaser has irrevocably accepted for payment all Dynavax shares validly tendered and not withdrawn under the offer.
Because the Sanofi group now holds more than the percentage of shares needed to approve the merger agreement, it plans to complete a merger under Section 251(h) of Delaware law without a Dynavax stockholder vote. At the merger’s effective time, each remaining Dynavax share (with limited exceptions such as treasury shares and properly perfected appraisal shares) will be converted into the right to receive the same $15.50 cash merger consideration. After the merger, Dynavax shares will be delisted from the NASDAQ Global Select Market and deregistered under the Exchange Act, ending public trading in the stock.
Sanofi, through Samba Merger Sub, has successfully completed its cash tender offer for Dynavax Technologies at $15.50 per share. The purchaser has irrevocably accepted for payment all Dynavax shares validly tendered and not withdrawn under the offer.
Because the Sanofi group now holds more than the percentage of shares needed to approve the merger agreement, it plans to complete a merger under Section 251(h) of Delaware law without a Dynavax stockholder vote. At the merger’s effective time, each remaining Dynavax share (with limited exceptions such as treasury shares and properly perfected appraisal shares) will be converted into the right to receive the same $15.50 cash merger consideration. After the merger, Dynavax shares will be delisted from the NASDAQ Global Select Market and deregistered under the Exchange Act, ending public trading in the stock.
Sanofi filed a 6-K summarizing three developments: regulatory progress for Rezurock, pivotal data for venglustat, and a new share buyback mandate.
The European regulator’s advisory committee issued a positive opinion recommending conditional EU marketing authorization for Rezurock to treat chronic graft-versus-host disease in adults and certain adolescents after other options are exhausted. This follows a re-examination of an earlier negative view and is based on clinical and real-world data, including a phase 2 study showing a 74% overall response rate.
Sanofi also reported that venglustat met the primary and most key secondary endpoints in a phase 3 trial for type 3 Gaucher disease and plans global regulatory filings. Separately, the company signed a mandate to repurchase up to €1 billion of its own shares between February 3 and December 31, 2026.
Sanofi, through Samba Merger Sub, is pursuing a cash tender offer to acquire all outstanding shares of Dynavax Technologies for $15.50 per share. This amendment reports that Germany’s Federal Ministry for Economic Affairs and Energy cleared the related Dynavax GmbH foreign investment transaction effective January 29, 2026.
The German foreign direct investment clearance had been a condition to acquiring 100% of the voting rights in Dynavax GmbH, a Dynavax subsidiary. With this regulatory approval in place, a key international review hurdle tied to the tender offer structure has been satisfied.